On the other hand, in triple-negative (that is, ER-negative, PR-negative and HER2-negative) breast cancers, even mutations affecting bona fide driver genes, such as TP53, have been shown to be heterogeneously distributed in a subset of cases [9]. This evidence concerns the gene TP53 and breast carcinoma.